Vi gör inga förändringar av våra estimat som redan återspeglar en starkare krona och lägre produktio...
Omsättningen sjönk till 6,6 (10,2) meur, varav PremierGaming stod för 5,8%.
Mendus has reported its Q225 results. During the period, it made continued progress on the lead prog...
Redeye provides a research update following the Q2 report published by OncoZenge earlier today.
Dovre’s Q2 saw even more losses, although financial position still appears decent so long as recent ...
Despite a weaker-than-expected quarter in terms of revenue and profitability, we are raising our sal...
Ascelia’s two most important value drivers are the US submission, which is now de-risked, and Asceli...
Redeye provides its initial take on Acarix’s Q2 report, which showed a year-on-year increase in both...
The sales number for Q2 had already been communicated and was slightly above our forecast.
* Sales -4% and adj. EBIT -11% vs ABGSCe * DOCS adoption 23% of municipalities * Consensus adj.
Redeye provides an initial comment on the Q2 2025 report from Catella.
* Sales -4% vs. ABGSCe at SEK 55m * EBITDA better than expected (SEK -0.
* Stable occupancy and positive net letting * Cons to lower estimates (rec.
* Q2 EBIT of SEK 315m, +11% vs. ABGSC and +7% vs. consensus * Announces buyback of bonds of max SEK ...
Redeye comments on Better Collective’s Q2-results which were slightly below our forecast owing mainl...
Redeye provides its initial take on Surgical Science’s Q2 2025 report, which aligned with its profit...
* Q2 in line, with automotive market and FX posing headwinds * Some uncertainty about targets, but v...
Redeye comments on SynAct Biopharma’s Q2 report. After a directed share issue, loan agreement with H...
Redeye provides an update following Paxman’s Q2 2025 report.
Investors House's Q2 report was overshadowed by the announcement that the board will propose an extr...